Blood Coagulation Factors ; antagonists & inhibitors ; Hemophilia A ; blood ; Humans

Objective To investigate the clinical significance and prognostic value of PKD3 expression in human hepatocellu-lar carcinoma (HCC)after hepatectomy.Methods We analyzed mRNA expression of L1CAM in 1 10 HCCs by quantitative real-time PCR (qRT-PCR)and western blot,and the relationship among the overall survival of HCCs.Results The relative protein and mRNA expression level of L1CAM was up-regulated in HCCs comparing with adjacent non tumor liver tissues (P <0.01).L1CAM expression in the well-differentiated group was higher than that in the poor-differentiated group (P < 0.01 ).The expression of L1CAM mRNA was significantly correlated with tumor differentiation and TNM stage (P <0.05).The prognosis of patients with high expression L1CAM was poor (P <0.01).Conclusion L1CAM expression is related to occurrence and development of HCCs and may predict the prognosis of HCCs after hepatectomy.

OBJECTIVE:To compare the cost-effectiveness of3therapeutic schemes on acute cerebral infarction(ACI).METHODS:A total of123patients with ACI were ascribed to receive sodium ozagrel injection(shemeⅠ),ginkgo leaf extract(GLE)and dipyridamole injection(schemeⅡ)and sodium ozagrel injection plus ginkgo leaf injection(schemeⅢ),the cost-effectiveness analyses of3groups were conducted using pharmacoeconomics method.RESULTS:The costs for the3schemes were9766.51yuan,5562.22yuan and8273.05yuan,respectively;The effective rates were36.84%,32.50%and71.11%,respectively;The cost-effectiveness ratios of3were265.11,171.15and116.34,respectively.CONCLUSION:SchemeⅢis preferable among3schemes.

OBJECTIVE:To evaluate the cost-effectiveness of 3 "Cocktail" therapeutic regimens in treating acute cerebral infarction(ACI).METHODS:141 patients with ACI were administered with Sodium Ozagrel + Cinepazide + Edaravone(Group A),Vinpocetine + Propylgallate + Deproteinized calf blood Extractives(Group B)or Sodium Ferulate + Buflomedil + Muscular Amino Acids and Peptides and Nucleosides(Group C)for 14d.Cost-effectiveness analysis in pharmacoeconomics was applied to analyze the therapeutic effects and costs.RESULTS:The total costs of 3 groups(A,B and C)were 5 970.67 yuan,4 865.11 yuan and 3 939.72 yuan,respectively,the efficiency rates were 82.98%,63.04% and 64.58% respectively,and the cost-effectiveness ratio were 7 195.31,7 717.50 and 6 100.53,respectively.CONCLUSION:Group A is preferable for ACI.

Blood Platelets ; Hematologic Diseases ; therapy ; Humans ; Platelet Aggregation Inhibitors ; therapeutic use

Fracture Fixation ; methods ; Humans ; Mandibular Condyle ; injuries ; Mandibular Fractures ; complications ; therapy ; Maxillary Fractures ; complications ; therapy ; Multiple Trauma ; complications ; mortality

Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Humans ; Purpura, Thrombotic Thrombocytopenic ; therapy ; Rituximab

Gray Platelet Syndrome ; Humans